These findings support those in recent similar reports of increased SARS-CoV-2-specific CD8+ T cell activation in anti-CD20 mAb–treated patients with MS (19, 24) and suggest that B cell depletion may result in compensatory changes in certain aspects of cellular immunity. This evidence concerns the gene CD8A and myeloid sarcoma.